Liposomal Cytarabine-Daunorubicin Cpx-351
Acute Megakaryoblastic Leukemia
Explore 6 assets in Acute Megakaryoblastic Leukemia →Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Rondeep Brar
Modality
unclassified
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02019069CT.gov CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Megakaryoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Liposomal Cytarabine-Daunorubicin Cpx-351 (this asset) | Rondeep Brar | P2 | B · 57 |
| Etoposide | Northwestern University | P3 | BBB |
| Cytarabine | University of Alberta | P3 | BBB |
| Daunomycin | ECOG-ACRIN Cancer Research Group | P3 | BBB |
| Cyclophosphamide | Fred Hutchinson Cancer Center | P3 | BBB |
| Idarubicin | University of Alberta | P3 | BBB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | BBB |
| Mitoxantrone | Stanford University | P2 | BBB |
| Nivestim | Rutgers, The State University of New Jersey | P3 | BB |
+42 more in the Acute Megakaryoblastic Leukemia cohort
Other indications for Liposomal Cytarabine-Daunorubicin Cpx-351
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia With Minimal Differentiation | — | P2 | B · 57 |
| Acute Monocytic Leukemia | — | P2 | B · 57 |
| Acute Erythroid Leukemia | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Liposomal Cytarabine-Daunorubicin Cpx-351 in Acute Megakaryoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/liposomal-cytarabine-daunorubicin-cpx-351-acute-megakaryoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →